Objective To evaluate the pharmacokinetics of a combined oral contraceptive (OC)
containing oestradiol valerate/dienogest (E2V/DNG) administered according to a four-phasic …

OBJECTIVE: A novel oral contraceptive (OC) that contains oestradiol valerate (E2V; 1mg of
E2V is equivalent to 0.76 mg of 17beta-oestradiol) and dienogest (DNG) has been …

The aim of this review is to define the role of the combined dienogest (DNG)/estradiol
valerate (E2V) contraceptive pill, in terms of biochemistry, metabolic and pharmacological …

Abstract▴ Estradiol valerate/dienogest is an oral contraceptive for women that combines the
natural estrogen estradiol with the 19-nortestosterone derivative dienogest in a four-phasic …

Most combination oral contraceptives contain ethinyl estradiol and a progestin. A new and
novel oral contraceptive formulation combines estradiol valerate (E2V) with dienogest …

Abstract Background and Objective: The hormonal components of combined oral
contraceptives (COCs) have various metabolic and haemostatic effects. The objective of this …

This study investigated the pharmacokinetics of a dose-reduced oral contraceptive
containing 20 μg ethinylestradiol (EE)+ 100 μg levonorgestrel (LNG) in 18 young, healthy …

Objective To summarise all clinical data on the contraceptive efficacy and bleeding profile
associated with an oestradiol valerate (E2V) and dienogest (DNG)[E2V/DNG] combined oral …

BACKGROUND: Estradiol valerate/dienogest (E2V/DNG) is a combined oral contraceptive
(COC) with 2 new hormonal entities and a unique 4-phasic dosing regimen indicated for …

BACKGROUND: We evaluated the effects of cytochrome P450 3A4 (CYP3A4) induction and
inhibition on steady-state pharmacokinetics of the components of a novel oral contraceptive …